+1 700 888 1234
Effingerstrasse 40 3008 Bern Switzerland
Our president Anne-Marie Baird had an active participation at the ESMO Congress as a speaker/chair. Our board members Erika Pataki, Lavinia Magee, Ewelina Szmytke, Debra Montague, and our Policy Officer, Alfonso Aguarón had a proactive contribution in multiple meetings.
See below for highlights from several of the ESMO 2023 sessions.
On Friday, 20th LuCE was invited to one of the Patient Advocacy Sessions where the discussion of ‘The importance of addressing caregivers’ needs: The perspective of caregivers’ took place. The presentation provided an opportunity for questions and discussion with a particular focus on how being a caregiver can have multiple side effects and what the caregiver’s needs are along the patient journey. The meeting included presentations from:
On Friday 20th, the presentation ‘’How to improve access to medicines through patient engagement?” took place, where LuCE was mentioned by MPE as we are too embarking on an Atlas Journey which will see the creation of strong advocacy tool addressing the inequities in access to treatment. The meeting included presentations from:
On Saturday 21st, the Workgroup of European Cancer Patient Advocacy Networks (WECAN) held its Members Meeting, in which our Policy Officer, Alfonso Aguarón was a part of. The discussion started on a project status update was presented for the initiatives of the 23 pan-European cancer patient organisations such as the European Atlas on Clinical Trials in Cancer and Haematology, the WECAN Evidence Based Advocacy Programme and finally, a discussion on the upcoming projects for 2024.
On Saturday 21st, our LuCE president Anne-Marie Baird was a chair for the presentation ‘’New approaches for technologies, therapies, and surgery” where the main discussion focused on AI as a new technology and how personalized treatment is part of the standard of care in tech management of patients. The meeting included presentations from:
On Saturday 21st, our LuCE President Anne-Marie Baird was a speaker for the presentation ‘’Managing disease progression in oncogene-driven lung cancer” where she focused on Mechanism of resistance, Broad overview, In vitro models, acquired resistance mutations, Bypass track, Evolutionary models, Tumour microenvironment. The meeting included presentations from: